These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 8232099)

  • 1. Proteinuria, hyperlipidemia, and the kidney.
    Hutchison FN
    Miner Electrolyte Metab; 1993; 19(3):127-36. PubMed ID: 8232099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction in proteinuria attenuates hyperlipidemia in the nephrotic syndrome.
    Kaysen GA; Davies RW
    J Am Soc Nephrol; 1990 Nov; 1(5 Suppl 2):S75-9. PubMed ID: 16989070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nephrotic hyperlipidemia: primary abnormalities in both lipoprotein catabolism and synthesis.
    Kaysen GA
    Miner Electrolyte Metab; 1992; 18(2-5):212-6. PubMed ID: 1465061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathogenesis of lipid abnormalities in patients with nephrotic syndrome/proteinuria: clinical implications.
    Warwick GL; Packard CJ
    Miner Electrolyte Metab; 1993; 19(3):115-26. PubMed ID: 8232098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Disturbances of lipid metabolism during nephrotic syndrome: physiopathology and treatment].
    Moulin B; Ollier J; Olmer M
    Nephrologie; 1992; 13(5):193-9. PubMed ID: 1470293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Nephrotic syndrome: pathophysiology, classification and diagnostic criteria].
    Togawa A; Yamamoto T; Hishida A
    Nihon Rinsho; 2004 Oct; 62(10):1777-83. PubMed ID: 15500118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Achieving maximal renal protection in nondiabetic chronic renal disease.
    Taal MW; Brenner BM
    Am J Kidney Dis; 2001 Dec; 38(6):1365-71. PubMed ID: 11728976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is the aggressive management of hyperlipidemia in nephrotic syndrome mandatory?
    Keane WF; St Peter JV; Kasiske BL
    Kidney Int Suppl; 1992 Oct; 38():S134-41. PubMed ID: 1405364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperlipidemia and progressive renal disease.
    Keane WF; Mulcahy WS; Kasiske BL; Kim Y; O'Donnell MP
    Kidney Int Suppl; 1991 Apr; 31():S41-8. PubMed ID: 2046270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statins in nephrotic syndrome: a new weapon against tissue injury.
    Buemi M; Nostro L; Crascì E; Barillà A; Cosentini V; Aloisi C; Sofi T; Campo S; Frisina N
    Med Res Rev; 2005 Nov; 25(6):587-609. PubMed ID: 16075407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperlipidemia and renal disease: the use of animal models in understanding pathophysiology and approaches to treatment.
    Stevenson FT; Kaysen GA
    Wien Klin Wochenschr; 1999 Apr; 111(8):307-14. PubMed ID: 10378311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipids and progressive kidney disease.
    Moorhead JF
    Kidney Int Suppl; 1991 Apr; 31():S35-40. PubMed ID: 2046269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of lipid abnormalities in the pathogenesis of chronic, progressive renal disease.
    Kasiske BL; O'Donnell MP; Schmitz PG; Keane WF
    Adv Nephrol Necker Hosp; 1991; 20():109-25. PubMed ID: 2063707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The hyperlipidemia of the nephrotic syndrome.
    Appel GB; Valeri A; Appel AS; Blum C
    Am J Med; 1989 Nov; 87(5N):45N-50N. PubMed ID: 2486547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression of renal failure: role of apolipoprotein B-containing lipoproteins.
    Attman PO; Samuelsson O; Alaupovic P
    Kidney Int Suppl; 1997 Dec; 63():S98-101. PubMed ID: 9407433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperlipidemia in childhood nephrotic syndrome.
    Thabet MA; Salcedo JR; Chan JC
    Pediatr Nephrol; 1993 Oct; 7(5):559-66. PubMed ID: 8251323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical state of a patient with nephrotic proteinuria successfully treated with combined therapy with angiotensin II receptor antagonists and angiotensin II converting enzyme inhibitors and pentoxifylline].
    Renke M; Rutkowski P; Tylicki L; Zietkiewicz M; Larczyński W; Rutkowski B
    Przegl Lek; 2008; 65(6):312-4. PubMed ID: 18853664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statins and renal diseases: from primary prevention to renal replacement therapy.
    D'Amico G
    J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S148-52. PubMed ID: 16565241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipids and the progression of renal disease.
    Keane WF; O'Donnell MP; Kasiske BL; Schmitz PG
    J Am Soc Nephrol; 1990 Nov; 1(5 Suppl 2):S69-74. PubMed ID: 16989069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of hyperlipidemia in human renal disease.
    D'Amico GD; Gentile MG
    Miner Electrolyte Metab; 1993; 19(3):196-204. PubMed ID: 8232107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.